Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine vs ECT in Treatment-Resistant Depression
NCT04924257Phase 3Withdrawn
- Sponsor
- Medical University of Innsbruck
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 4 weeks. Planned start Jul 2021; status: withdrawn.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04924257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924257.